Drug General Information (ID: DDI5DNCM3P)
Drug Name			Dornase alfa		Drug Info		Insulin human (inhalation, rapid acting)		Drug Info
Drug Type		Protein/peptide				Hormones
Therapeutic Class		Antiviral Agents				Insulin/Antidiabetic Agents

Mechanism of Dornase alfa-Insulin human (inhalation, rapid acting) Interaction (Severity Level: Moderate)
Altered absorption (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Dornase alfa				Insulin human (inhalation, rapid acting)
Mechanism		Alter the absorption of inhaled human insulin				Inhaled human insulin
Key Mechanism Factor 1
		Factor Name		Pharmacokinetic
		Factor Description		Alters the absorption of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects.
Mechanism Description		Altered absorption of Insulin human (inhalation, rapid acting) caused by Dornase alfa

Recommended Action
Management		Consistent timing of dosing of other inhaled products relative to inhaled human insulin administration is recommended. Blood glucose should be monitored closely, and the insulin dose adjusted accordingly.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
3	Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72. [PMID: 6781341]